Valeo Financial Advisors LLC boosted its position in Stryker Co. (NYSE:SYK) by 81.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,631 shares of the medical technology company’s stock after buying an additional 3,870 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Stryker were worth $2,102,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the business. Tower View Investment Management & Research LLC lifted its holdings in Stryker by 9.0% in the 4th quarter. Tower View Investment Management & Research LLC now owns 510 shares of the medical technology company’s stock worth $125,000 after buying an additional 42 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Stryker by 0.5% in the 4th quarter. Van ECK Associates Corp now owns 8,681 shares of the medical technology company’s stock worth $2,127,000 after buying an additional 42 shares in the last quarter. BBR Partners LLC lifted its holdings in Stryker by 3.4% in the 4th quarter. BBR Partners LLC now owns 1,272 shares of the medical technology company’s stock worth $312,000 after buying an additional 42 shares in the last quarter. Sepio Capital LP lifted its holdings in Stryker by 4.3% in the 4th quarter. Sepio Capital LP now owns 1,043 shares of the medical technology company’s stock worth $256,000 after buying an additional 43 shares in the last quarter. Finally, Concentric Wealth Management LLC lifted its holdings in Stryker by 0.3% in the 4th quarter. Concentric Wealth Management LLC now owns 16,972 shares of the medical technology company’s stock worth $4,159,000 after buying an additional 44 shares in the last quarter. Hedge funds and other institutional investors own 71.46% of the company’s stock.
In other news, CFO Glenn S. Boehnlein sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, March 1st. The shares were sold at an average price of $246.01, for a total value of $492,020.00. Following the completion of the sale, the chief financial officer now directly owns 12,321 shares of the company’s stock, valued at approximately $3,031,089.21. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.80% of the company’s stock.
NYSE SYK traded up $0.52 on Monday, hitting $253.84. The stock had a trading volume of 3,767 shares, compared to its average volume of 1,234,281. Stryker Co. has a one year low of $168.49 and a one year high of $253.46. The company has a quick ratio of 2.15, a current ratio of 2.89 and a debt-to-equity ratio of 0.92. The stock has a market cap of $95.53 billion, a price-to-earnings ratio of 54.95, a P/E/G ratio of 2.79 and a beta of 0.87. The company’s 50-day moving average is $240.66 and its two-hundred day moving average is $232.43.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 26th. The medical technology company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.55 by $0.26. The company had revenue of $4.26 billion during the quarter, compared to analyst estimates of $4.33 billion. Stryker had a net margin of 12.35% and a return on equity of 20.94%. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.49 EPS. On average, sell-side analysts anticipate that Stryker Co. will post 7.18 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 30th. Stockholders of record on Wednesday, March 31st will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date of this dividend is Tuesday, March 30th. Stryker’s dividend payout ratio is currently 30.51%.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.